A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Autor: Alkhouri, Naim, Edwards, Katherine, Berman, Mark, Finn, Heather, Escandon, Rafael, Lupinacci, Paul, Guthrie, Nicole, Coste, Angie, Topete, Jesus, Noureddin, Mazen

Publikováno v: In Gastro Hep Advances 2024 3(1):9-16

FRI-515 - A novel prescription digital therapeutic for the treatment of non-alcohol related fatty liver disease: feasibility study

Autor: Alkhouri, Naim, Edwards, Katherine, Berman, Mark, Rudolf, Erin, Finn, Heather, Dusky, Heidi, Guthrie, Nicole, Escandon, Rafael, Coste, Angie, Topete, Jesus, Noureddin, Mazen

Publikováno v: In Journal of Hepatology June 2023 78 Supplement 1:S822-S823

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Autor: Alkhouri N; Fatty Liver Program, Arizona Liver Health, Chandler, Arizona., Edwards K; Better Therapeutics, San Francisco, California., Berman M; Better Therapeutics, San Francisco, California., Finn H; Better Therapeutics, San Francisco, California., Escandon R; DGBI Consulting, LLC, Bainbridge Island, Washington., Lupinacci P; Villanova University, Villanova, Pennsylvania., Guthrie N; Better Therapeutics, San Francisco, California., Coste A; Fatty Liver Program, Arizona Liver Health, Chandler, Arizona., Topete J; Fatty Liver Program, Arizona Liver Health, Chandler, Arizona., Noureddin M; Houston Methodist Hospital, Houston Research Institute, Houston, Texas.

Publikováno v: Gastro hep advances [Gastro Hep Adv] 2023 Oct 01; Vol. 3 (1), pp. 9-16. Date of Electronic Publication: 2023 Oct 01 (Print Publication: 2024).